Avacta Promotes Francis Wilson to Chief Scientific Officer Amid Leadership Transition
Event summary
- Francis Wilson, previously Vice President of Chemistry, promoted to Chief Scientific Officer effective February 9, 2026.
- Wilson has been instrumental in developing Avacta's pre|CISION® platform, particularly the sustained release mechanism for the FAP-Exd (AVA6103) program.
- Former CSO Michelle Morrow departs to pursue another opportunity.
- Wilson brings over 35 years of experience in medicinal chemistry, including leadership roles at Roche, Xenova, Cellzome, and Summit Therapeutics.
The big picture
Avacta's promotion of Francis Wilson to CSO underscores the company's focus on advancing its pre|CISION® platform, particularly as it prepares for clinical testing of the FAP-Exd program. The transition follows a period of significant preclinical development and intellectual property generation, positioning Avacta to compete in the tumor-activated oncology delivery space. Wilson's extensive experience in medicinal chemistry and drug development will be critical as the company navigates this next phase of growth.
What we're watching
- Clinical Progress
- The pace at which the FAP-Exd (AVA6103) program advances into clinical testing will signal Avacta's execution capabilities.
- IP Expansion
- Whether Wilson can sustain the generation of novel intellectual property around the pre|CISION® platform.
- Leadership Impact
- How Wilson's scientific leadership influences Avacta's positioning in the international drug development sector.
Related topics